Bharat Biotech

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI's Expert Panel

Covaxin Supplies At Rs 150/Dose ‘Non-Competitive Price, Not Sustainable’: Bharat Biotech Defends Higher Price

No Emergency Use Approval For Covaxin In US; Phase 3 Trial Data Expected To Be Published In 7-8 Days, Says Dr VK Paul

Covid Vaccine Prices To Be Revised, Centre In Talks With Serum Institute & Bharat Biotech: Sources

Early Covaxin Study Shows Protections Against Beta & Delta Variants Of Covid-19

Covishield Elicits Better Antibody Response Than Covaxin: Study

AIIMS Delhi To Begin Covaxin Trials On Children Today Amid Third Wave Scare

Biological E’s Corbevax At Rs 250/Dose May Be Cheapest Covid-19 Vaccine In India

'More Info Required': WHO To Bharat Biotech As It Submits ‘90% Documents’ For Emergency Use Listing Of Covaxin

'Why Is Centre Preventing Bharat Biotech From Sharing Vaccine Formula If They Are Ready?': CM Kejriwal

Delhi HC Refuses to Stay Covaxin Clinical Trial On Children; Issues Notice to Centre, DGCI

Covaxin Effective Against Covid Variants Found In India & UK: Bharat Biotech